image credit: Freepik

Targeted Protein Degradation Represents a Promising Therapeutic Strategy

Despite enormous efforts to advance traditional pharmacology approaches, more than three quarters of all human proteins remain beyond the reach of therapeutic development, according to scientists from the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna. They maintain that targeted protein degradation (TPD) is a novel approach that could overcome this and other limitations, and thus represents a promising therapeutic strategy.

TPD is based on small molecules (known as degraders), which can eliminate disease-causing proteins by causing their destabilization. Mechanistically, these degrader drugs repurpose the cellular protein quality control system, tweaking it to recognize and eliminate harmful proteins.

Read More on Genetic Engineering and Biotechnology News